FAKHRAVAC

Source: Wikipedia, the free encyclopedia.

FAKHRAVAC
FakhraVac vaccine 01 (cropped).jpg
A vial of FakhraVac
Vaccine description
TargetSARS-CoV-2
Vaccine typeInactivated
Clinical data
Other namesFakhra, MIVAC
Routes of
administration
Intramuscular
Legal status
Legal status
  • Emergency use authorization: IRN

FAKHRAVAC is a COVID-19 vaccine developed in Iran by the Organization of Defensive Innovation and Research,[1] a subsidiary of Iran's Ministry of Defense. It's the third Iranian COVID-19 vaccine reaching clinical trials.[1][2][3] It's currently in phase III.[4][5] It has received emergency use authorization in Iran on 9 September 2021.[4]

The vaccine is named after the Iranian nuclear scientist Mohsen Fakhrizadeh.[1] According to the Iranian authorities, he was working on a vaccine in response to the COVID-19 pandemic in Iran.[1][6] Fakhrizadeh was assassinated in November 2020 in an attack Iran and US intelligence attributed to Israel.[1][7]

Medical uses

It requiring two doses given by intramuscular injection 3 weeks apart.[5]

Pharmacology

FAKHRAVAC is an inactivated virus-based vaccine.[3]

Manufacturing

On August 2021, production capacity of the vaccine is reported to be 1 million dose per month and is planned to be "multiplied in a few months ".[4]

Clinical trials

Clinical trials of FAKHRAVAC
Phase Registration number Start Number of participants Age of participants
Total Vaccine Control
I IRCT20210206050259N1 8 March 2021 135 96? 39? (placebo) 18-55 years
II IRCT20210206050259N2 8 June 2021 500 250 250 (placebo) 18-70 years
III IRCT20210206050259N3 29 August 2021 41,128 20,564 20,564 (Sinopharm vaccine) >18 years

Authorizations

The vaccine received emergency use authorization in Iran on 9 September 2021.[4]


References

  1. ^ a b c d e Motamedi M (16 March 2021). "Iran starts human trials of its third domestic COVID vaccine". Al Jazeera.
  2. ^ "Phase 1, safety, immunogenicity and dose finding for two strengths of 0.5 × 10^6 and 2.5 × 10^6 (TCID50) inactivated SARS-CoV-2 vaccine FAKHRAVAC (MIVAC) injected in two schedules of two doses, 2 and 3 weeks apart in healthy adults aged 18-55 years: a randomized, double blind, placebo controlled, clinical trial". en.irct.ir. Iran Registry of Clinical Trials. Retrieved 21 March 2021.
  3. ^ a b "Phase 2 trial of safety and immunogenicity of 10 micro gram inactivated SARS-CoV-2 vaccine (FAKHRAVAC), two doses two weeks apart in adults aged 18-70 years: a randomized, double-blind, placebo-controlled, clinical trial". en.irct.ir. Iran Registry of Clinical Trials. Retrieved 15 June 2021.
  4. ^ a b c d "Iran Authorizes Emergency Use of Third Homegrown Vaccine - Defense news". Tasnim News Agency. Retrieved 9 September 2021.
  5. ^ a b "IRCT | Comparison of the safety, efficacy and immunogenicity of Fakhravac and Sinopharm SARS-CoV-2 vaccines, in adults aged 18 and over; a phase III randomised, non-inferiority clinical trial". en.irct.ir. Retrieved 7 September 2021.
  6. ^ "Research center run by Fakhrizadeh produced first COVID-19 test kits for Iranians: Defense minister". Pars Today. 28 November 2020. Archived from the original on 5 December 2020. Retrieved 7 September 2021.
  7. ^ The Assassination of Fakhrizadeh: Considerations and Consequences
This page is based on the copyrighted Wikipedia article: FAKHRAVAC. Articles is available under the CC BY-SA 3.0 license; additional terms may apply.